At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 124 enrolled
Drug / intervention
tamoxifendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen
In Brief
A Phase 2 clinical trial evaluating tamoxifen for Breast Cancer and Stage IV Breast Cancer. Completed, enrolled 124 participants across 294 sites in 3 countries.
Detailed Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight cancer by blocking the use of estrogen by tumor cells. PURPOSE: This phase II trial is studying how well tamoxifen citrate works in patients with metastatic or recurrent breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Stage IV Breast Cancer
CountriesCanada, Peru, United States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartJan 2011
Primary CompletionNov 2020
Study CompletionDec 2022
TodayJul 2026
First PostedMay 17, 2010
Enrollment StartJan 7, 2011
Primary CompletionNov 30, 2020
Study CompletionDec 1, 2022
TodayJul 2, 2026
Enrollment to primary: 9.9 yearsPosted 16.1 years ago
Interventions
tamoxifendrug
PO